Results 151 to 160 of about 17,710 (254)
Case Report Concerning a Varicella Zoster Virus Infection in a Six-year-old Child Receiving Dupilumab for Atopic Dermatitis. [PDF]
Rangen JK, Dalager MG.
europepmc +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Oliver Brandt +2 more
wiley +1 more source
The SWITCH algorithm: An expert consensus on treat‐to‐target criteria for chronic prurigo
The SWITCH project assessed patients' most distressing symptoms and therapy goals, followed by an expert‐based consensus procedure to define T2T criteria for patients with chronic prurigo (CPG)/prurigo nodularis. Based on these validated criteria, a 4‐step SWITCH algorithm was established to enhance CPG therapy outcomes and reduce patient burden ...
Lea S. Stahl +16 more
wiley +1 more source
Vaccinating patients on biologics for atopic disease: Clinical considerations and evidence-based recommendations. [PDF]
Chase NM.
europepmc +1 more source
Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer +10 more
wiley +1 more source
Dupilumab and cutaneous T-cell lymphoma: A retrospective cohort study. [PDF]
Baghdasarian S, Al-Saedi O, Cuomo RE.
europepmc +1 more source
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat +22 more
wiley +1 more source
Renal Disease Burden in Prurigo Nodularis: A Systematic Review and Meta‐Analysis
International Journal of Dermatology, EarlyView.
Natalia Chalupczak +3 more
wiley +1 more source
Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis
The results of this French Early Access Program were consistent with those reported in dupilumab randomized clinical trials in children aged 6 months–5 years with moderate‐to‐severe AD. This research offers insights into the practical use of dupilumab in routine clinical practice.
Audrey Lasek +9 more
wiley +1 more source

